Huafu Securities: Initiates coverage on Dongyang Sun Pharmaceuticals (06887.HK) with a "Buy" rating. Rich innovation pipeline with strong growth potential.

Zhtng Cijng APP huxn, Huf zhngqun fb ynbo chng, Dng Ynggung yo (06887.HK) zuwi lign lngdo qy, jbn pn wng, qi chungxn gunxin chbi fngf, chngzhng xng qing, jjio kng gnrn, mn bng y zhngl sn d bnkui. Kng gnrn lngy zi lign, cngn, ygn gunxin boch lngxin dwi. Shuc fgi giy "mir" pngj. According to the Zhtng Cijng APP, Huf Securities has released a research report stating that Dongyang Guangyao (06887.HK), as a leading company in the flu field, has a solid customer base and rich innovative pipeline reserves, showing strong growth potential, focusing on three major sectors: anti-infection, chronic diseases, and tumors. In the field of anti-infection, it maintains a leading position in the pipelines of flu, hepatitis C, and hepatitis B. It was first covered with a "buy" rating.